1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Etern Biopharma (Shanghai) Co. Ltd. has 1 pending office action currently under review. This matter is assigned to 1 distinct examiner, KOSACK, JOSEPH R, who is responsible for 1 pending office action. The application is located within 1 distinct art unit. This singular focus on one examiner and one art unit means the company immediate prosecution results depend on a single point of contact within the patent office. The presence of 1 pending office action indicates that the company is currently managing a narrow administrative footprint. This focused activity suggests that the company current strategy is centered on a single technical disclosure.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KOSACK, JOSEPH R | 1 | 74.8% | -6.1% |
| Art Unit | Apps |
|---|---|
| 3991 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18837121 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | KOSACK, JOSEPH R | 3991 | §112 | Non-Final OA | — | Pending | Aug 08, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEtern Biopharma (Shanghai) Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Joseph R Kosack has the most, with 1 of Etern Biopharma (Shanghai) Co. Ltd.'s pending office actions.
